Presenter Information

Tajai Sion-MilliganFollow

Location

Schewel 232

Access Type

Open Access

Presentation Type

Oral Presentation

Start Date

4-4-2018 1:15 PM

Department

Biology

Abstract

One in eight women in the United States will be diagnosed with breast cancer. Approximately 25-30% of these breast tumors will overexpress Human Epidermal Growth Factor Receptor 2 (HER2), associated with a worse prognosis and decreased survival rate. Stimulation of HER2 results in activation and production of many signaling molecules, ultimately resulting in increased cell division. Two of the downstream molecules activated are PI3Kinase and, further downstream, the molecule Akt. Typically, overproduction and/or overactivation of PI3Kinase can lead to oncogenesis. A molecule that may have a significant role in PI3Kinase formation is VAV1. VAV1 is produced via the stimulation of the Epidermal Growth Factor Receptor, a family member of HER2. VAV1 may mediate PI3Kinase’s ability to further activate downstream pathways. This study utilized small-interfering RNA (siRNA) to “knock-down” expression of VAV1. Once VAV1 is not expressed, activation of PI3Kinase and Akt can be tested to determine the necessity of VAV1 in this signaling pathway. Effects of the knock-down of VAV1 will be assessed using Western blotting with antibodies identifying phosphorylated PI3 Kinase, an indicator of activation.

PI3Kinase and Akt can be tested to determine the necessity of VAV1 in this signaling pathway. Effects of the knock-down of VAV1 will be assessed using Western blotting with antibodies identifying phosphorylated PI3 Kinase, an indicator of activation.

Faculty Mentor

Dr. Jablonski

Rights Statement

The right to download or print any portion of this material is granted by the copyright owner only for personal or educational use. The author/creator retains all proprietary rights, including copyright ownership. Any editing, other reproduction or other use of this material by any means requires the express written permission of the copyright owner. Except as provided above, or for any other use that is allowed by fair use (Title 17, §107 U.S.C.), you may not reproduce, republish, post, transmit or distribute any material from this web site in any physical or digital form without the permission of the copyright owner of the material.

Share

COinS
 
Apr 4th, 1:15 PM

siRNA Knock-down of Vav1 in Breast Cancer Cells: Effects on PI3Kinase and Akt

Schewel 232

One in eight women in the United States will be diagnosed with breast cancer. Approximately 25-30% of these breast tumors will overexpress Human Epidermal Growth Factor Receptor 2 (HER2), associated with a worse prognosis and decreased survival rate. Stimulation of HER2 results in activation and production of many signaling molecules, ultimately resulting in increased cell division. Two of the downstream molecules activated are PI3Kinase and, further downstream, the molecule Akt. Typically, overproduction and/or overactivation of PI3Kinase can lead to oncogenesis. A molecule that may have a significant role in PI3Kinase formation is VAV1. VAV1 is produced via the stimulation of the Epidermal Growth Factor Receptor, a family member of HER2. VAV1 may mediate PI3Kinase’s ability to further activate downstream pathways. This study utilized small-interfering RNA (siRNA) to “knock-down” expression of VAV1. Once VAV1 is not expressed, activation of PI3Kinase and Akt can be tested to determine the necessity of VAV1 in this signaling pathway. Effects of the knock-down of VAV1 will be assessed using Western blotting with antibodies identifying phosphorylated PI3 Kinase, an indicator of activation.

PI3Kinase and Akt can be tested to determine the necessity of VAV1 in this signaling pathway. Effects of the knock-down of VAV1 will be assessed using Western blotting with antibodies identifying phosphorylated PI3 Kinase, an indicator of activation.